Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR)

NCT ID: NCT06328101

Last Updated: 2024-03-25

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-05-01
• Study Completion Date: 2025-04-01

Brief Summary

The goal of this observational, retrospective study is to learn about cancer risk in autoimmune pancreatitis (AIP) patients. The main questions it aims to answer are:

• Do patients with AIP have higher incidence of cancer in comparison to general population?
• What is the overall prevalence of cancer in AIP patients?
• What are the characteristics of AIP patients associated with the incidence of cancer?

Detailed Description

Autoimmune pancreatitis (AIP) is a relapsing form of pancreatitis, comprising two histological entities with differing clinical, serological, and prognostic characteristics. Type 1 AIP is a pancreatic manifestation of IgG4-related disease, while type 2 AIP is an isolated pancreatic disorder strongly associated with the simultaneous occurrence of inflammatory bowel disease (IBD). AIP patients, particularly type 1, face a risk of relapse and may develop exocrine and endocrine pancreatic insufficiency. While it's widely acknowledged that chronic pancreatitis increases the risk of pancreatic cancer, the association between AIP and pancreatic cancer remains more controversial. AIP can imitate pancreatic cancer, and coincidence has been reported. Retrospective data from Japan suggested a high risk of pancreatic cancer and bile duct cancer in patients with AIP. However, there is a paucity of specific data on the relationship between AIP and pancreatic cancer. Japanese studies have suggested a higher incidence of extrapancreatic cancer in AIP patients compared to the general population. German single-center data support this claim. The most frequently reported cancers include lung, gastric, and prostate cancer, constituting approximately 50% of all cancers detected at or after the diagnosis of AIP. However, the time span of both AIP and cancer was not defined and might have introduced bias. Available data need to be interpreted with caution as no studies have yet compared the incidence of the most common cancers in AIP patients directly to age-grouped and gender-matched controls in the general population.

To address this lack of knowledge a worldwide, multicenter, retrospective cohort study of AIP patients is initiated founded in the Pancreas2000 framework. With this trial cancer incidence and prevalence will be assessed for AIP patients and compared to age-matched controls.

The trial is based on a REDCap questionnaire containing following information.

1. Demographic details Month and year of birth Survival status month and year of death, if applicable Gender (Male, Female) Ethnicity (Caucasian, Hispanic, African, Asian, Arabic, Other, Unknown) Weight and height for the purpose of calculating body mass index Tobacco status (Current, Former, Never) incl. "smoking pack-years" if applicable Alcohol consumption (Current daily, current occasionally, Former, Never, Not available) History of other autoimmune diseases (not IgG4-related) (No, Sjögren's' syndrome, Rheumatoid arthritis, Sarcoidosis, Autoimmune thyroiditis (NOT IgG4 related), Other) History of inflammatory bowel disease (Yes, No, Unknown) Family history of cancer (Yes, No, Unknown)

2. AIP characteristics Month and year of diagnosis AIP The classification system used for original diagnosis (ICDC, HISORT, Asian, Unify) ICDC diagnosis type (Type 1, Type 2, Not otherwise specified (NOS) AIP) ICDC diagnosis level (Definite, Probable) ICDC parameters fulfilled for diagnosis (Histology, Serum IgG4, Imaging, Improvement after steroid treatment, Other organ involvement) Serum IgG4 (1-2 over upper limit, >2 over the upper limit, >4 over the upper limit) Imaging (Focal enlargement, Whole organ enlargement (sausage-like), Other) Other organ involvement (Salivary/lacrymal glands, Retroperitoneum/ kidneys, Bile ducts/liver, Musculoskeletal system, Gastrointestinal tract: Intestines, colon, esophagus, Vasculitis (e.g., aortitis), Enlarged lymph nodes, IBD) Presenting symptoms of AIP (None, Jaundice, Acute pancreatitis, Weight loss, Abdominal pain, New onset of diabetes) Medical treatment for AIP (Prednisone, Rituximab, Azathioprine, 6-mercaptopurine, Methotrexate, Mycophenolate mofetil, other) Interventional treatment for AIP (Partial pancreatectomy, Biliary stent placement, Other) AIP relapse (No relapse, 1-2 relapse(s), 3-4 relapses, >5 relapses, Unknown) AIP-related complications (No, Diabetes mellitus, Pancreatic exocrine insufficiency, Other) Month and year of last contact

3. Cancer Diagnosis Month and year of diagnosis of cancer Number of cancer diseases (1,2,3,4) Cancer type (list according to the World Health Organization) Cancer-related death (yes, no) In case of more than one cancer, specifically which cancer caused death

Conditions

Autoimmune Pancreatitis Type 1; Autoimmune Pancreatitis Type 2

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

AIP_mlg

Autoimmune pancreatitis patients with cancer

No interventions assigned to this group

AIP_nomlg

Autoimmune pancreatiits patients without cancer

No interventions assigned to this group

general population

Cancer Incidence in Five Continents Volume XI" (CI5XI) registry patients used to determine expected cancer incidence and calculate SIR

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Patients diagnosed with AIP after 2005, including type 1, type 2, and not-otherwise-specified (NOS) AIP, regardless of the diagnostic criteria used.

Exclusion Criteria

• Patients younger than 18 years at last contact
• Patients with less than 12 months of follow up after diagnosis
• Patients with immune checkpoint inhibitor-induced pancreatitis

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Medical Centre Maribor

OTHER

Sponsor Role: collaborator

Aalborg University Hospital

OTHER

Sponsor Role: collaborator

University Hospital Munich

OTHER

Sponsor Role: collaborator

Tartu University Hospital

OTHER

Sponsor Role: collaborator

University Hospital in Halle

OTHER

Sponsor Role: collaborator

University Medical Center Goettingen

OTHER

Sponsor Role: lead

Responsible Party

Christoph Ammer-Herrmenau

Medical Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Cecilie Siggaard Knoph, MD

Role: PRINCIPAL_INVESTIGATOR

Univesity Hospital Alborg

Julian Cardinal von Widdern, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Halle (Saale)

Karri Kasse, MD

Role: PRINCIPAL_INVESTIGATOR

Tartu University Hospital

Ivonne Regel, PhD

Role: STUDY_CHAIR

University Hospital of Munich (LMU)

Jonas Rosendahl, MD, PhD

Role: STUDY_CHAIR

University Hospital Halle (Saale)

Central Contacts

Sara Nikolić, MD

Role: CONTACT

s.nikolic91@gmail.com

+38651261676

Christoph Ammer Herrmenau, MD

Role: CONTACT

christoph.herrmenau@med.uni-goettingen.de

+491704075339

References

Lohr JM, Beuers U, Vujasinovic M, Alvaro D, Frokjaer JB, Buttgereit F, Capurso G, Culver EL, de-Madaria E, Della-Torre E, Detlefsen S, Dominguez-Munoz E, Czubkowski P, Ewald N, Frulloni L, Gubergrits N, Duman DG, Hackert T, Iglesias-Garcia J, Kartalis N, Laghi A, Lammert F, Lindgren F, Okhlobystin A, Oracz G, Parniczky A, Mucelli RMP, Rebours V, Rosendahl J, Schleinitz N, Schneider A, van Bommel EF, Verbeke CS, Vullierme MP, Witt H; UEG guideline working group. European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. United European Gastroenterol J. 2020 Jul;8(6):637-666. doi: 10.1177/2050640620934911. Epub 2020 Jun 18.

Reference Type: BACKGROUND

PMID: 32552502 (View on PubMed)

Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, Kim MH, Kloppel G, Lerch MM, Lohr M, Notohara K, Okazaki K, Schneider A, Zhang L; International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011 Apr;40(3):352-8. doi: 10.1097/MPA.0b013e3182142fd2.

Reference Type: BACKGROUND

PMID: 21412117 (View on PubMed)

Nikolic S, Lanzillotta M, Panic N, Brismar TB, Moro CF, Capurso G, Della Torre E, Lohr JM, Vujasinovic M. Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature. United European Gastroenterol J. 2022 Jun;10(5):496-506. doi: 10.1002/ueg2.12237. Epub 2022 May 8.

Reference Type: BACKGROUND

PMID: 35526270 (View on PubMed)

Lee HW, Moon SH, Kim MH, Cho DH, Jun JH, Nam K, Song TJ, Park DH, Lee SS, Seo DW, Lee SK. Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. J Gastroenterol. 2018 Aug;53(8):967-977. doi: 10.1007/s00535-018-1434-6. Epub 2018 Jan 23.

Reference Type: BACKGROUND

PMID: 29362937 (View on PubMed)

Lanzillotta M, Tacelli M, Falconi M, Arcidiacono PG, Capurso G, Della-Torre E. Incidence of endocrine and exocrine insufficiency in patients with autoimmune pancreatitis at diagnosis and after treatment: a systematic review and meta-analysis. Eur J Intern Med. 2022 Jun;100:83-93. doi: 10.1016/j.ejim.2022.03.014. Epub 2022 Mar 30.

Reference Type: BACKGROUND

PMID: 35367110 (View on PubMed)

Nikolic S, Maisonneuve P, Dahlman I, Lohr JM, Vujasinovic M. Exocrine and Endocrine Insufficiency in Autoimmune Pancreatitis: A Matter of Treatment or Time? J Clin Med. 2022 Jun 28;11(13):3724. doi: 10.3390/jcm11133724.

Reference Type: BACKGROUND

PMID: 35807009 (View on PubMed)

Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A, Domellof L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993 May 20;328(20):1433-7. doi: 10.1056/NEJM199305203282001.

Reference Type: BACKGROUND

PMID: 8479461 (View on PubMed)

Kurita Y, Kubota K, Fujita Y, Tsujino S, Sekino Y, Kasuga N, Iwasaki A, Iwase M, Izuka T, Kagawa K, Tanida E, Yagi S, Hasegawa S, Sato T, Hosono K, Kobayashi N, Ichikawa Y, Nakajima A, Endo I. IgG4-related pancreatobiliary diseases could be associated with onset of pancreatobiliary cancer: A multicenter cohort study. J Hepatobiliary Pancreat Sci. 2024 Mar;31(3):173-182. doi: 10.1002/jhbp.1404. Epub 2023 Dec 20.

Reference Type: BACKGROUND

PMID: 38124014 (View on PubMed)

Shiokawa M, Kodama Y, Yoshimura K, Kawanami C, Mimura J, Yamashita Y, Asada M, Kikuyama M, Okabe Y, Inokuma T, Ohana M, Kokuryu H, Takeda K, Tsuji Y, Minami R, Sakuma Y, Kuriyama K, Ota Y, Tanabe W, Maruno T, Kurita A, Sawai Y, Uza N, Watanabe T, Haga H, Chiba T. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol. 2013 Apr;108(4):610-7. doi: 10.1038/ajg.2012.465. Epub 2013 Jan 15.

Reference Type: BACKGROUND

PMID: 23318486 (View on PubMed)

Schneider A, Hirth M, Munch M, Weiss C, Lohr JM, Ebert MP, Pfutzer RH. Risk of Cancer in Patients with Autoimmune Pancreatitis: A Single-Center Experience from Germany. Digestion. 2017;95(2):172-180. doi: 10.1159/000455963. Epub 2017 Feb 23.

Reference Type: BACKGROUND

PMID: 28226313 (View on PubMed)

Cardinal von Widdern J, Knoph CS, Kase K, Regel I, Rosendahl J, Ammer-Hermenau C, Nikolic S. Autoimmune pancreatitis, pancreatic and extrapancreatic cancer (AIPPEAR): a multicentre, retrospective study protocol. BMJ Open. 2025 Feb 16;15(2):e086824. doi: 10.1136/bmjopen-2024-086824.

Reference Type: DERIVED

PMID: 39956600 (View on PubMed)

Other Identifiers

2023-02558

Identifier Type: -

Identifier Source: org_study_id